Ensysce Biosciences is a shell companies business based in the US. Ensysce Biosciences shares (LACQ) are listed on the PINK and all prices are listed in US Dollars.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| 52-week range | $0.00 - $0.00 |
|---|---|
| 50-day moving average | $13.97 |
| 200-day moving average | $13.65 |
| Wall St. target price | N/A |
| PE ratio | 118.7705 |
| Dividend yield | N/A |
| Earnings per share (TTM) | $0.12 |
Valuing Ensysce Biosciences stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Ensysce Biosciences's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Ensysce Biosciences's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 119x. In other words, Ensysce Biosciences shares trade at around 119x recent earnings.
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -1.25% |
| Return on equity TTM | 23.4% |
| Profit margin | 0% |
| Book value | $0.30 |
| Market Capitalization | $90.2 million |
TTM: trailing 12 months
We're not expecting Ensysce Biosciences to pay a dividend over the next 12 months.
Over the last 12 months, Ensysce Biosciences's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (PINK average) beta is 1, while Ensysce Biosciences's is -0.1134. This would suggest that Ensysce Biosciences's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Ensysce Biosciences has bucked the trend.
Ensysce Biosciences, Inc. operates as a biotechnology company that develops abuse-resistant drug technologies. It offers TAAP, a trypsin-activated abuse protection technology that prevents abuse through a two-step internal trypsin-activation process to meet the medical needs of patients living with chronic pain; and MPAR, a multi-pill abuse resistant technology that provides a layer of protection for overdose. The company was incorporated in 2003 and is based in La Jolla, California. .
These are the stocks to buy when you don’t have much to spend.
Cash sweep accounts let you earn interest on your uninvested cash. Learn how they work and how to choose the best one here.
These are the best discount brokers of 2025 according to Finder’s comprehensive review.
Compare the 7 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
We review the Kalshi trading platform and explain how investors can use it as a hedge for their investments.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
Compare pros, cons, research tools and reviews for these two trading platforms.
Fractional shares are fractions of company shares. Sometimes they’re made by brokers to allow those with limited funds to get access to stocks.
SoFi Invest is a no-fee commissions platform with both active and automated investment accounts.
Webull is a broker with zero-commission trading and a suite of tools to help you invest.